Ruxolitinib Phosphate and its Impurities

Ruxolitinib Phosphate, sold under the brand names Jakafi and Jakavi, is a medication for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow.Ruxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. Reference standards of Ruxolitinib Phosphate API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.